CAS: 801-52-5; Azirino[2',3':3,4]Pyrrolo[1,2-A]Indole-4,7-Dione,6-Amino-8-[[(Aminocarbonyl)Oxy]Methyl]-1,1A,2,8,8A,8B-Hexahydro-8A-Methoxy-1,5-Dimethyl-,(1As,8S,8Ar,8Bs)

该化合物是来自微切片家族的抗生素和抗直肠剂,属于微切片家族,它作为电动剂发挥作用,诱导DNA交叉链接,抑制核酸合成,使其对某些细菌感染和固态肿瘤有效,在缺氧条件下的生物传导增强了其针对肿瘤微环境的选择性,减少了系统毒性.Porfiromycin在综合疗法中的潜力,特别是在治疗抗常规治疗的缺氧癌症细胞方面的潜力,其稳定性和行动机制使其成为肿瘤学和抗微生物应用研究的宝贵化合物.

结构式图片

MSDS等安全信息

    上下游产品

    CAS号50-07-7 丝裂霉素C | CAS号74-88-4 碘甲烷 | CAS号77-78-1 硫酸二甲酯 | CAS号4055-39-4 丝裂霉素A | CAS号18209-14-8 N-methylmitomycin A

    合成工艺路线路线简述

      📜丝裂霉素 A 反应生成 泊非霉素
      参考文献:J. Org. Chem. 1985,50,1301-1302
      标题:J. Org. Chem. 1985,50,1301-1302

      海关参考信息

      专利信息


      专利号:US-2012177593-A1
      优先权日:2009-07-20
      标 题 :Synthesis of dendrimer conjugates
      发明人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
      权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
      摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

      专利号:US-10973847-B2
      优先权日:2017-06-30
      标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof
      发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R
      权利人:MASSACHUSETTS INST TECHNOLOGY
      摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.

      专利号:US-12391691-B2
      优先权日:2018-11-16
      标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
      发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
      权利人:AMGEN INC
      摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

      专利号:US-2025206736-A1
      优先权日:2019-11-14
      标题 :Synthesis of kras g12c inhibitor compound
      发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
      权利人:AMGEN INC
      摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

      专利号:WO-2017100796-A1
      优先权日:2015-12-11
      标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
      发明人:WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI
      权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING
      摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.

      专利号:US-2017283878-A1
      优先权日:2015-12-11
      标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
      发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING
      权利人:ACADEMIA SINICA
      摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Haffty BG, Wilson LD, Son YH, Cho EI, Papac RJ, Fischer DB, Rockwell S, Sartorelli AC, Ross DA, Sasaki CT, Fischer JJ. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):119-28.
      7: Sartorelli AC, Belcourt MF, Hodnick WF, Keyes SR, Pritsos CA, Rockwell S. Preferential kill of hypoxic EMT6 mammary tumor cells by the bioreductive alkylating agent porfiromycin. Adv Enzyme Regul. 1995;35:117-30.

      合成参考文献


      摘要:National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program., JAN1986
      摘要:Compounds Available for Fundamental Research, Volume II-6, Antibiotics, A Program of Upjohn Company Research Laboratory., 2(6)(-), 1971
      参考文献:10.1007/s00280-001-0410-6
      摘要:Kelner MJ, McMorris TC, Rojas RJ, Trani NA, Estes L. Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C. Cancer Chemother Pharmacol. 2002 May;49(5):412–8. doi: 10.1007/s00280-001-0410-6.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知